Results 221 to 230 of about 34,864,199 (249)

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review. [PDF]

Blood Adv
Rankin AW, Myers RM, Lamble AJ, Hsieh EM, Sankaran H, Chen L, Annesley C, DiNofia AM, Grupp SA, Pulsipher MA, Dolan JG, Bhojwani D, Gardner RA, Shah NN, Rheingold SR.   +14 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Prospective Study of Interventional Radiology-Guided PICC Insertions in Oncology Patients: Incidence and Risk Factors for Complications in an LMIC Cohort

Indian Journal of Radiology and Imaging
Ravi Najabhai Karmata, Amit Gupta, Sheragaru H. Chandrashekhara, Maroof Ahmad Khan, Sachidanand Jee Bharti, Mukesh Kumar   +5 more
doaj   +1 more source

Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah's Witness Patient With Ph-Negative B-ALL. [PDF]

Am J Case Rep
Koilpillai S, Altaf R, El Barche Palmera A, Hassanein H, Carlan SJ.   +4 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. [PDF]

Adv Sci (Weinh)
Ng HL, Glaser TL, Zhu J, Robinson ME, Cosgun KN, Malysheva V, Deniz O, Crump NT, Helian K, Innes AJ, Burt R, Sun L, John G, Zhou H, Kaneshige A, Bai L, Wang S, Spivakov M, Müschen M, Feldhahn N.   +19 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Deletion of 9p drives B-ALL through heterozygous inactivation of Pax5 and Cd72 in preleukemic cells. [PDF]

JCI Insight
Ruiz-Corzo B, Casado-García A, Oak N, Somoza-Cotillas P, López-Álvarez de Neyra A, Martínez-Cano J, Pérez-Pons A, Sánchez EG, Blanco O, Alonso-López D, De Las Rivas J, Riesco S, Prieto-Matos P, García Criado FJ, García Cenador MB, Orfao A, Ramírez-Orellana M, Cobaleda C, Vicente-Dueñas C, Nichols KE, Sánchez-García I.   +20 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines. [PDF]

Int J Hematol
Ida N, Okura M, Tanaka S, Hosono N, Yamauchi T.   +4 more
europepmc   +1 more source